Richard Ulevitch
From Wikipedia, the free encyclopedia
 |
This article or section reads like an advertisement. Please help rewrite this article from a neutral point of view per Wikipedia policy. Mark blatant advertising for speedy deletion with {{db-spam}}. (help, talk) |
Richard Ulevitch, PhD, is Chairman of the Department of Immunology at The Scripps Research Institute. For nearly three decades, Dr. Ulevitch has performed research to identify the basic mechanisms of the innate immune response to infection. His research has led to a number of seminal discoveries, including the definition of the function of receptors in the innate immune system recognizing bacterial products and the discovery of a signal transduction cascade essential for an appropriate innate immune response and for regulating the production of key mediators of inflammation. A number of his findings are currently being translated into drug development in the areas of acute and chronic inflammation and septic shock. He is the author of more than 200 scientific articles and his work has been among the most highly cited publications in the field of Immunology. In addition to his scientific achievements, Dr. Ulevitch has been affiliated with multiple advisory panels including the National Institutes of Health, the American Heart Association, and the Food and Drug Administration. He is currently a scientific advisor to Aravis Ventures (Zurich, Switzerland), to 5AM Ventures (Menlo Park, CA) and a consultant to biotechnology and pharmaceutical companies. He was a a founding scientific advisor to the Lombard Odier Darier Hentsch Immunology Fund (Geneva, Switzerland). Currently Dr. Ulevitch serves as Chairman of 5AM Venture's Scientific Advisory Board. Dr. Ulevitch has an AB from Washington and Jefferson College and a PhD in Biochemistry from the University of Pennsylvania.
